Table 4 Mean AUC values for irinotecan and its metabolites

From: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours

 

AUC μ g ml −1  h (CV, %)

 

Irinotecan

SN-38

SN-38 glucuronide

APC

 

Cycle 1

Cycle 2

Cycle 1

Cycle 2

Cycle 1

Cycle 2

Cycle 1

Cycle 2

Dose levels 1–3 (n=10)

11.6 (25)

11.9 (28)

0.518 (62)

0.539 (57)

0.838 (33)

0.909 (43)a

2.24 (59)a

2.25 (44)

Dose levels 4 and 5 (n=13)

14.9 (41)

16.0 (51)

0.587 (113)

0.640 (87)

0.876 (66)

1.043 (77)

1.61 (37)b

1.34 (40)a

Cycle 2 vs cycle 1 (% change±95% CI)

+6.2 (±10.1)

+16.4 (±20.2)

+15.3 (±13.0)

−19.3% (±15.3)

P-value

NS

NS

<0.05

<0.05

  1. AUC=area under the curve; SN-38=7-ethyl-10-hydroxycamptothecin; APC=7-ethyl-10-[4-N-(5-aminopeptanoic acid)-1-piperidino]-carbonyloxycamptothecin; NS=not significant.
  2. aNot available for one patient.
  3. bNot available for two patients.
Back to article page